Art Van Zee—Purdue Pharma

Art Van Zee’s relationship with Purdue Pharma became a prolonged contest over what was driving OxyContin-related harm in rural Virginia: the drug’s availability and promotion, as Van Zee argued, or drug abuse and undertreated pain, as the company maintained. A country doctor’s local reports grew into public challenges, demands for product changes, and a recall campaign, making the dispute a concrete example of the distance between community experience and corporate explanation.

Local warnings and the company’s response

Within weeks of recognizing that the problem in his region was not isolated, Van Zee organized public meetings through the Lee Coalition for Health, a grassroots group of ministers, social workers, and other community-minded residents. His wife, Sue Ella Kobak, helped edit and coach him as he wrote Purdue Pharma about patterns he was seeing: people injecting the drug, frequent overdoses, abscesses, and rising hepatitis C. His initial approach was to ask the company to investigate its prescribing patterns, not merely to describe a general concern about addiction.

In a letter dated August 20, 2000, Van Zee told Purdue Pharma medical director David Haddox that the extent of the problem was difficult to overstate. A second letter warned that the affected communities might be sentinel areas, where early signs of a larger epidemic could be seen. The concern had already entered the company’s own correspondence: in May 2000, a Purdue medical response addressed reports of young people crushing, snorting, and injecting OxyContin, as well as hospital visits involving overdoses and injection-related abscesses. Purdue replied to Van Zee by sending him and his medical partner Adverse Event Report Forms. The exchange placed local observations on record, but the paperwork did not amount to the investigation or product changes Van Zee sought.

The disagreement was also visible at a forum for area doctors and families. Van Zee brought in Yale University substance-abuse experts to explain the physical and psychological strain of opioid withdrawal and the long, often relapse-filled course of opioid addiction. When the researchers recommended that doctors consider other drugs less prone to abuse for patients with severe pain, a Purdue Pharma representative who had attended incognito stood up to challenge the recommendation. The representative argued that inadequate pain treatment, rather than OxyContin abuse, was the central problem. The encounter brought the competing explanations into the same room: clinical concern about a particular drug’s risks against an industry argument rooted in the broader problem of undertreated pain.

From concern to demands for change

As the dispute continued, Van Zee’s requests became specific. He asked Purdue Pharma to stop aggressively marketing OxyContin for noncancer pain and to reformulate it so that it would be less susceptible to abuse. To show that a medication could be altered to reduce diversion, he pointed to the makers of Talwin, who had added the narcotic antagonist naloxone in a 1982 reformulation and thereby reduced misuse. His proposals treated the product’s design and promotion as practical points of intervention, not as distractions from the need to treat pain.

By November 2000, his letters had sharpened in tone. They described patients making a five-hour round trip to Knoxville, Tennessee, for maintenance methadone, including a twenty-three-year-old woman who left at four in the morning with her four-year-old daughter. The example connected the drug problem to the scarcity and distance of treatment: the visible consequences of OxyContin misuse were not, for Van Zee, separable from the burden placed on families seeking care. At the same time, he attended a meeting of the Appalachian Pain Foundation, a Purdue-funded professional association that amplified the pain-management movement’s argument that pain remained undertreated. The setting made clear that the dispute unfolded amid a genuine debate about pain care, even as Van Zee challenged how that debate was being used to defend OxyContin’s promotion.

He also confronted Purdue Pharma over promotional incentives offered to doctors. On leaving a meeting, he told Haddox that physician freebies needed to stop. Haddox responded by asking how the practice differed from that of other drug companies. Van Zee’s reply distinguished OxyContin from ordinary consumer products: people were not stealing from family members or breaking into neighbors’ homes over blood-pressure medication. His point was that the consequences he was documenting demanded a response beyond the claim that the company’s practices were standard within the industry.

Public campaign and widening conflict

In early 2001, Van Zee and the Lee Coalition for Health launched a petition drive asking the Food and Drug Administration to order an OxyContin recall. The campaign transformed his correspondence with Purdue Pharma into a public challenge to the drug’s continued availability. More than ten thousand people signed, most of them from Lee County. A standing-room-only town hall at the local high school in March drew eight hundred attendees, with some sitting in the auditorium aisles. The turnout brought the scale of community concern into public view and further separated Van Zee from much of the local medical establishment and the industry he was confronting.

The local campaign coincided with evidence of wider consequences in nearby Tazewell County, Virginia. Between August 1999 and August 2000, 150 people had been charged with OxyContin-related felonies in a county of 44,000, and ten drugstore robberies had occurred in eighteen months. Those figures gave force to Van Zee’s contention that the crisis could not be reduced to an abstract debate over pain treatment. In April 2001, the Drug Enforcement Administration developed a national action plan asking Purdue Pharma to limit distribution, rethink its marketing, and consider making the drug abuse-resistant. The agency’s decision to target a specific drug for manufacturer action was unprecedented in its history. It did not itself establish that Purdue Pharma accepted Van Zee’s account, but it showed that concerns over diversion had moved beyond local protest.

Competing explanations and the relationship’s significance

Purdue Pharma continued to frame the dispute around abuse rather than the drug. In August 2001, a company spokesman told Virginia’s attorney general that OxyContin should not be blamed for deaths because some victims had also used alcohol or other drugs. Van Zee rejected that reasoning in remarks to a Roanoke Times reporter, using an analogy to argue that the presence of a lesser contributing factor did not make the more powerful one irrelevant. The disagreement was not simply over whether drug abuse existed; it was over whether the product’s potency, circulation, and promotion belonged at the center of the explanation.

The conflict also shaped Van Zee’s understanding of who would be heard. He came to doubt that federal authorities would take a country doctor’s warnings seriously while the damage remained concentrated among poor people in mountain communities; he believed wider attention would come only when opioid abuse reached cities and suburbs. The later recognition that OxyContin misuse had been treated as a problem of particular communities, rather than as an urgent public concern, gave his early letters a significance beyond their requests for an investigation. Their record shows a local physician identifying specific harms, proposing changes, and meeting repeated defenses that shifted attention toward pain treatment or individual abuse. The relationship with Purdue Pharma thus stands at the intersection of two claims: that pain had long been undertreated, and that addressing pain did not excuse overlooking the risks created by a heavily promoted drug.